Change 5-day change 1-year change 3-year change Capi.($)
-16.67%-16.67% - - 4.97K
+0.60%-1.78%+20.46%+9.90% 216B
-1.51%-4.68%-5.38%-21.06% 142B
+0.22%-0.56%-18.55%+34.85% 138B
-1.87%+0.02%-51.08%-0.92% 74.53B
+0.19%-1.14%+16.25%+18.42% 52.34B
+1.18%+0.74%-16.17%-14.38% 50.28B
-0.01%-0.19%+24.53%+22.83% 41.93B
-1.59%-2.55%+37.63%+46.89% 40.06B
+0.36%-0.43%-1.05%+6.20% 32.69B
Average -1.91%-0.52%+0.74%+11.41% 87.63B
Weighted average by Cap. -0.22%-1.16%-0.21%+9.08%
Logo SpectraScience, Inc.
SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.
Employees
-